摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-phenyl-2H-benzo[b][1,4]oxazin-2-one | 1630972-64-3

中文名称
——
中文别名
——
英文名称
6-phenyl-2H-benzo[b][1,4]oxazin-2-one
英文别名
——
6-phenyl-2H-benzo[b][1,4]oxazin-2-one化学式
CAS
1630972-64-3
化学式
C14H9NO2
mdl
——
分子量
223.231
InChiKey
CEYPZVFBZVSHKC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.86
  • 重原子数:
    17.0
  • 可旋转键数:
    1.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    43.1
  • 氢给体数:
    0.0
  • 氢受体数:
    3.0

反应信息

  • 作为反应物:
    描述:
    6-phenyl-2H-benzo[b][1,4]oxazin-2-onephenyl isocyanoacetate2-(二苯基膦基)-N-[(8Α,9S)-6'-甲氧基奎宁-9-基]苯甲酰胺silver(l) oxide 作用下, 以 四氢呋喃 为溶剂, 生成 phenyl 4-oxo-8-phenyl-3a,4-dihydro-3H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxylate
    参考文献:
    名称:
    异氰基乙酸酯对α-亚氨基酯的高度非对映和对映选择性银催化的双[3 + 2]双环化
    摘要:
    本文介绍了一种新的复杂性产生方法,其中α-亚氨基酯的两个官能团均与异氰基乙酸酯进行立体选择性环化反应,以生成直接连接的恶唑-咪唑啉,然后可以将其转化为高度官能化的α,β-二氨基酯和咪唑啉鎓盐。 -和对映体纯度。
    DOI:
    10.1002/anie.201402788
  • 作为产物:
    描述:
    乙醛酸乙酯3-氨基-4-羟基联苯甲苯 为溶剂, 反应 24.0h, 以84%的产率得到6-phenyl-2H-benzo[b][1,4]oxazin-2-one
    参考文献:
    名称:
    异氰基乙酸酯对α-亚氨基酯的高度非对映和对映选择性银催化的双[3 + 2]双环化
    摘要:
    本文介绍了一种新的复杂性产生方法,其中α-亚氨基酯的两个官能团均与异氰基乙酸酯进行立体选择性环化反应,以生成直接连接的恶唑-咪唑啉,然后可以将其转化为高度官能化的α,β-二氨基酯和咪唑啉鎓盐。 -和对映体纯度。
    DOI:
    10.1002/anie.201402788
点击查看最新优质反应信息

文献信息

  • Copper-catalyzed direct coupling of benzoxazin-2-ones with indoles for the synthesis of diverse 3-indolylbenzoxazin-2-ones: access to natural cephalandole A
    作者:Rameshwar Prasad Pandit、Jae-Jin Shim、Sung Hong Kim、Yong Rok Lee
    DOI:10.1039/c7ra10634c
    日期:——
    A novel and facile copper-catalyzed direct coupling for the synthesis of diverse and functionalized 3-indolyl benzoxazin-2-ones from benzoxazin-2-ones and indoles has been developed. This new methodology offers an easy and rapid approach to a variety of 3-indolylbenzo[b][1,4]oxazin-2-ones in high yield. As an application of this protocol, a gram-scale synthesis of naturally occurring cephalandole A
    已经开发了一种新颖且容易的催化直接偶联反应,用于从苯并恶嗪-2-酮和吲哚合成各种功能化的3-吲哚基苯并恶嗪-2-酮。这种新方法为高产率地制备各种3-吲哚基苯并[ b ] [1,4]恶嗪-2-酮提供了一种简便快捷的方法。作为该方案的应用,还已经完成了天然存在的头孢烯酮A的克级合成。
  • Transition-Metal-Free Alkylation and Acylation of Benzoxazinones with 1,4-Dihydropyridines
    作者:Youjung Byun、Junghyea Moon、Won An、Neeraj Kumar Mishra、Hyung Sik Kim、Prithwish Ghosh、In Su Kim
    DOI:10.1021/acs.joc.1c01558
    日期:2021.9.3
    vital transformation for the development of pharmaceuticals, functional materials, and other chemical entities. Herein, the transition-metal-free alkylation and acylation of C(sp2)–H bonds in biologically relevant 2-benzoxazinones with 1,4-dihydropyridines as readily accessible radical surrogates is described. Excellent functional group compatibility and a broad substrate scope were attained. Gram-scale
    N-杂环的直接功能化是药物、功能材料和其他化学实体开发的重要转变。在此,描述了生物相关 2-苯并恶嗪酮中的 C(sp 2 )-H 键与 1,4-二氢吡啶作为易于获得的自由基替代物的无过渡属烷基化和酰化。获得了优异的官能团兼容性和广泛的底物范围。通过 Suzuki 与杂芳基硼酸偶联合成的加合物的克级反应和转化证明了所开发方案的合成潜力。
  • Silver-catalyzed cross-dehydrogenative coupling of benzoxazine-2-ones with resorcinol
    作者:Yumi Kang、Soomin Jeon、Hayoung Kim、Jonghyeok Han、Garam Choi、Eun-Kyu Sun、Rameshwar Prasad Pandit、Tae-Hyun Kim
    DOI:10.1016/j.tetlet.2022.154184
    日期:2022.11
    Silver-catalyzed cross-dehydrogenative coupling of benzoxazin-2-ones with resorcinol is reported. This method provides an easy and direct C3-arylation of benzoxazin-2-ones at ambient condition at the expenses of inexpensive ammonium persulfate as an oxidant. A radical pathway has been proposed for the transformation.
    报道了催化的 benzoxazin-2-ones 与间苯二酚的交叉脱氢偶联。该方法以廉价的过硫酸作为氧化剂为代价,在环境条件下提供了一种简单直接的苯并恶嗪-2-酮的 C3-芳基化。已经提出了一种激进的转型途径。
  • B(C6F5)3/Chiral Phosphoric Acid Catalyzed Asymmetric Aza-Diels–Alder Reaction of Imines and Unactivated Dienes
    作者:Zhen Liu、Qing-Chun Qian、Li-Ming Chen、Xin Li
    DOI:10.1021/acs.orglett.4c00874
    日期:2024.4.19
    Herein, we report an asymmetric aza-Diels–Alder reaction of quinoxalinones or benzoxazinones with unactivated dienes by utilizing a B(C6F5)3/chiral phosphoric acid catalyst to construct chiral six-membered N-heterocycles. Various quinoxalinones or benzoxazinones with electron-withdrawing and electron-donating groups and unactivated dienes were tolerated (up to 99% yield and 99% ee) in the methodology
    在此,我们报道了利用B(C 6 F 5 ) 3 /手性磷酸催化剂构建手性六元N杂环,喹喔啉酮或苯并恶嗪酮与未活化二烯的不对称氮杂狄尔斯-阿尔德反应。在该方法中,仅使用 2 mol % 的催化剂负载量,即可耐受各种具有吸电子基团和给电子基团的喹喔啉酮或苯并恶嗪酮以及未活化的二烯(高达 99% 的产率和 99% ee)。此外,还对产品的发光机理和光物理性能进行了测试,并将其用于二维码防伪。
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione